The Segal Cancer Centre has been forging partnerships with other provincial, national and international research groups as part of its commitment to conducting cutting-edge fundamental, translational and clinical research in cancer and providing training for the next generation of cancer researchers.
Quebec - Clinical Research Organization in Cancer (Q-CROC)
Q-CROC is a new multidisciplinary and multi-institutional group of specialists whose main objectives are to enhance the Quebec clinical research infrastructure and capacity, to establish a translational research network focusing on therapeutic resistance of metastatic cancer and to expand public awareness about clinical trials as a means of enhancing participation and recruitment.
The 1st Quebec Conference on Therapeutic Resistance in Cancer, organized by Q-CROC, had the objective of bringing this problem to the forefront and regrouping the clinical and research communities around this scientific issue.
In May 2009 Pfizer Canada, in partnership with the Fonds de la recherche en santé Québec (FRSQ) and its Cancer Research Network, announced a $1.25 million investment to Q-CROC. Further information can be found on the communiqué from FRSQ.
Worldwide Innovative Network (WIN)
The Worldwide Innovative Network was formed in 2009 to promote research and the development of personalized medicine for the treatment of cancer. Launched at the inaugural symposium in July 2009, the consortium founders are internationally renowned academic institutions from Europe, Asia and North America, including the Segal Cancer Centre. Dr. Gerald Batist, Director of the Segal Cancer Centre, is a member of the new consortium's Steering Committee, and Dr. Alan Spatz, representing the Segal Cancer Centre and its McGill affiliation, as well as Q-CROC, spoke at the symposium.
McGill Integrated Cancer Research Training Program (MICRTP)
In 2008 The Montreal Centre for Experimental Therapeutics in Cancer (McGill Centre for Translational Research in Cancer) at the Segal Cancer Centre and the McGill Cancer Centre (now called the Goodman Cancer Centre) decided to strengthen their existing strategic training programs by merging them into one program called the McGill Integrated Cancer Research Training Program. The new CIHR/FRSQ training program whose Principal Investigators are Dr. Michel Tremblay (Goodman Cancer Centre) and Dr. Wilson Miller (Segal Cancer Centre), was funded in 2009 for 6 years to provide training for graduate students and postdoctoral fellows.